Budget Impact of Long-Acting Insulin Analogues: The Case in Brazil

摘要

BackgroundLong-acting insulin analogues for type 1 diabetes (T1D) treatment have been available on the Brazilian market since 2002. However, the population cannot access the analogues through the public health system.